(Q35527141)

8 August 2017

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab (English)

1 reference

8 August 2017

1 reference

1 reference

Uterine serous carcinoma

1 reference

1 reference

P Todeschini

1

1 reference

8 August 2017

E Cocco

2

1 reference

8 August 2017

S Bellone

3

1 reference

8 August 2017

J Varughese

4

1 reference

8 August 2017

K Lin

5

1 reference

8 August 2017

L Carrara

6

1 reference

8 August 2017

F Guzzo

7

1 reference

8 August 2017

N Buza

8

1 reference

8 August 2017

P Hui

9

1 reference

8 August 2017

D-A Silasi

10

1 reference

8 August 2017

E Ratner

11

1 reference

8 August 2017

M Azodi

12

1 reference

8 August 2017

P E Schwartz

13

1 reference

8 August 2017

T J Rutherford

14

1 reference

8 August 2017

S Pecorelli

15

1 reference

8 August 2017

A D Santin

16

1 reference

8 August 2017

language of work or name

English

0 references

publication date

13 September 2011

1 reference

British Journal of Cancer

8 August 2017

1 reference

8 August 2017

105

1 reference

8 August 2017

8

1 reference

8 August 2017

1176-1182

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.369

8 August 2017

0 references

cites work

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

The management of serous papillary uterine cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Identification and characterization of c-erbB-2 proteins in serum, breast tumor tissue, and SK-BR-3 cell line

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

c-erbB2 amplification and overexpression in human tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

12 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.369

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.369

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.369

Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.369

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.369

HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.369

Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

Overexpression of HER-2/neu in uterine serous papillary cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208497

The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage

26 September 2018

1 reference

12 December 2020

Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro

1 reference

12 December 2020

Clinical significance of Her-2/neu overexpression in uterine serous carcinoma

1 reference

12 December 2020

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2011.369

1 reference

8 August 2017

1 reference

8 August 2017

1 reference